| Literature DB >> 32600531 |
Soumya V L Vig1, Elcin Zan1, Stella K Kang2.
Abstract
Patients with renal cell carcinoma may develop metastases after radical nephrectomy, and therefore monitoring with imaging for recurrent or metastatic disease is critical. Imaging varies with specific suspected site of disease. Computed tomography/MRI of the abdomen and pelvis are mainstay modalities. Osseous and central nervous system imaging is reserved for symptomatic patients. Radiologic reporting is evolving to reflect effects of systemic therapy on lesion morphology. Nuclear medicine studies compliment routine imaging as newer agents are evaluated for more accurate tumor staging. Imaging research aims to fill gaps in treatment selection and monitoring of treatment response in metastatic renal cell carcinoma.Entities:
Keywords: CT; MRI; Metastatic disease; PET; Renal cell carcinoma
Mesh:
Year: 2020 PMID: 32600531 PMCID: PMC7327136 DOI: 10.1016/j.ucl.2020.04.005
Source DB: PubMed Journal: Urol Clin North Am ISSN: 0094-0143 Impact factor: 2.241